OVERVIEW

Assessment and Management of Insomnia: Recognizing the Role of Primary Care is organized by Center for Independent Healthcare Education, LLC and Vemco MedEd, LLC.

Release Date: Monday, December 9, 2019
Expiration Date: Wednesday, December 9, 2020

Accreditation:
Physicians
Center designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Educational Overview:
Sleep is increasingly being recognized as an important contributor to health. A growing body of evidence is supporting an association between poor sleep quality and duration with reduced quality of life as well as adverse cardiometabolic effects, including obesity, hypertension, type 2 diabetes, and cardiovascular disease. Appropriate management of sleep disorders can potentially improve management of chronic medical conditions, such as improved glycemic control in patients with type 2 diabetes mellitus. Though cognitive and behavioral therapy are commonly considered first-line treatments, the use of pharmacologic agents is needed in a large proportion of patients with sleep disorders. With the rapid decline in the number of sleep labs and certified sleep physicians over the past few years, diagnosis and management of sleep disorders is increasingly being relied upon by primary care providers (PCPs). However, PCPs may not be aware of the broad impact of poor sleep quality in their patients. This activity addresses these unmet needs in primary care in order to improve patient outcomes.

Learning Objectives:
At the conclusion of the educational activity, the learner should be able to:
• Describe the impact of insomnia on a patient’s quality of life and overall well-being
• Identify communication strategies aimed to improve the assessment of patient sleep quality to support earlier detection of potential sleep disorders
• Compare and contrast the benefits and risks of newer sleep medications, such as dual orexin receptor antagonists (DORAs), with traditional pharmacotherapeutic agents in the treatment of insomnia